Cite
HARVARD Citation
Magro, F. et al. (2019). Low Golimumab Trough Levels at Week 6 Are Associated With Poor Clinical, Endoscopic and Histological Outcomes in Ulcerative Colitis Patients: Pharmacokinetic and Pharmacodynamic Sub-analysis of the Evolution Study. Journal of Crohn's and colitis. pp. 1387-1393. [Online].